Melbourne-based Imagion Biosystems (ASX: IBX), a company focused on the earlier detection of cancer, has announced the appointment of Dr Oliver Steinbach as Vice President of Clinical and Regulatory Affairs.
The company said Dr Steinbach will serve as the lead executive in the development and execution of its overall clinical and regulatory strategy, focusing in the near-term on initiating the first-in-human study for HER2 metastatic breast cancer this year.
Dr Steinbach has more than 20 years of pharmaceutical, diagnostics and medical device industry experience, bringing multiple diagnostic and image-guided therapy products through the clinic into the market.
Dr Steinbach spent eight years at ALTANA Pharma and 12 years at Philips, where he was part of the Clinical Research group that managed clinical studies and regulatory submissions related to diagnostic, therapeutic and pharmaceutical products including molecular imaging contrast agents.
“We are very excited to have Oliver join Imagion,” said Bob Proulx, Executive Chairman. “His experience in managing clinical collaborations for medical imaging products is ideal for our organisation. This hire comes at just the right time as we are moving into the first phase of clinical work.
"After having raised $3.3M in a Rights Offering in November 2019, the Company is now using the funds to complete the initial steps of its upcoming first-in-human study for HER2 metastatic breast cancer. This includes manufacturing of its proprietary nanoparticles and gaining regulatory and clinical site authorisation for the study."